Merck
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
August 12, 2024Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells
Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
August 7, 2024Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …
CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
July 29, 2024Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …
FDA approves Merck’s Capvaxive for prevention of pneumococcal disease
June 18, 2024Medical Communications Capvaxive, FDA, Infections and infestations, Merck, pneumonia
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
Merck to acquire EyeBio for an upfront $1.3bn
May 31, 2024Business Services EyeBio, Merck, Opthalmology, acquisition, ophthalmology
Merck, known as MSD outside of the US and Canada, and EyeBiotech Limited, have announced that the two companies have …
Merck shares data from phase 3 trial of Keytruda for TNBC treatment
May 29, 2024Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda
Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …
Merck to acquire Mirus Bio for $600m
May 23, 2024Business Services Merck, Pharmacy, acquisition, gene therapies
Merck has announced that it has signed a definitive agreement to acquire Mirus Bio for $600m.
Merck shares data from phase 3 trial of Keytruda for gastric cancers
May 2, 2024Research and Development Gastric, MSD, Merck, Oncology, keytruda
Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …
TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
April 10, 2024Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …
FDA approves Merck’s Winrevair for PAH treatment
March 27, 2024Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
Merck shares results for Keytruda in cervical cancer treatment
March 18, 2024Research and Development Merck, Oncology, cervical cancer, keytruda, women's health
Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, …
Merck plans to conduct trials for HPV vaccines
March 13, 2024Research and Development Immunology, Merck, vaccines
Merck, known as MSD outside of the US and Canada, has announced that it is planning to initiate clinical development …
Merck completes acquisition of Harpoon Therapeutics for $650m
March 12, 2024Business Services Harpoon Therapeutics, Merck, Oncology, lung cancer
Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon …
Gilead and Merck share data from phase 2 trial of HIV treatment
March 7, 2024Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …
Merck to acquire Harpoon Therapeutics for approximately $680m
January 10, 2024Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …
